T2 Biosystems, Inc., a leading provider of rapid detection solutions for sepsis-causing pathogens and antibiotic resistance genes, announced that it will release its financial results for the first quarter of 2024 on May 6, 2024, after the market closes. The company will also provide business updates during this time. A conference call hosted by management will begin at 4:30 p.m. Eastern Time on the same day.
Investors who wish to listen to the conference call can access a live and archived webcast of the event at www.t2biosystems.com on the Investors page in the Events & Presentations section. To participate in the call, dial 1-888-506-0062 (US/Canada) or 1-973-528-0011 (International) with the passcode 160751 approximately ten to five minutes before the start time.
T2 Biosystems is committed to improving patient care and reducing healthcare costs by providing clinicians with fast and accurate diagnostics tools that enable them to treat patients more efficiently. The company’s product lineup includes several innovative solutions such as the T2Dx Instrument, the T2Bacteria Panel, the T2Candida Panel, the T2Resistance Panel, and the T2Biothreat Panel, which all utilize proprietary T2 Magnetic Resonance (T
Israel has long been known for producing great startups in industries such as cybersecurity, fintech,…
It is unfortunate that extremist groups were able to influence the decision to cancel the…
Snake Island, a small island located off the coast of Brazil, is home to one…
At the 2024 Core Hydration Classic women’s gymnastics meet, the top results were announced on…
In a thrilling contest at the Kingdom Arena in Riyadh, Tyson Fury was dwarfed by…
Toshiba has recently announced plans to launch hard drives with capacities exceeding 30TB in the…